SCHEMBL2979385

SCHEMBL2979385

COc1cccc(-c2cnc3sc(S(N)(=O)=O)nn23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 9/20 0.49
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA9 Q16790 3/20 0.46
CA4 P22748 2/20 0.46
CA5A P35218 2/20 0.46
CA5B Q9Y2D0 2/20 0.46
CA12 O43570 1/20 0.46
CA3 P07451 1/20 0.46
CA6 P23280 1/20 0.46
CA7 P43166 1/20 0.46
CA13 Q8N1Q1 1/20 0.46
CA14 Q9ULX7 1/20 0.46
PTGS2 P35354 2/20 0.44
DYRK1A Q13627 1/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2977119 0.94 PTGS2 (0.45) FYNCA1CA2CA9CA4
SCHEMBL2969001 0.85 CA12 (0.51) FYNCA1CA2CA9CA4
SCHEMBL3542403 0.85 DYRK1A (0.56) FYNDYRK1A
SCHEMBL3813038 0.83 PIK3CA (0.46) FYNCA1CA2CA9CA4
SCHEMBL2977197 0.83 CA12 (0.52) FYNCA1CA2CA9CA4
SCHEMBL2977228 0.82 CA12 (0.48) FYNCA1CA2CA9CA4
SCHEMBL2972797 0.82 FYN (0.52) FYNCA1CA2CA9CA4
SCHEMBL2972815 0.82 FYN (0.47) FYNCA1CA2CA9CA4
SCHEMBL2980003 0.82 FYN (0.45) FYNCA1CA2CA9CA4
SCHEMBL2540291 0.81 MEN1 (0.53) FYNCA1CA2CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772260-B2 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-08-10 US disclosed
US-7741349-B2 Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-06-22 US disclosed
US-7714003-B2 Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-05-11 US disclosed
US-7700635-B2 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-04-20 US disclosed
EP-1463735-B1 IMIDAZO¬2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES AEGERA THERAPEUTICS INC (CA) 2009-08-12 EP disclosed
US-20090042953-A1 IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES AEGERA THERAPEUTICS, INC. (CA) 2009-02-12 US disclosed
US-20070265319-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-11-15 US disclosed
US-20070238768-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-10-11 US disclosed
US-20070238766-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-10-11 US disclosed
US-7230019-B2 Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-06-12 US disclosed
US-20070088059-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides PHARMASCIENCE INC. (CA) 2007-04-19 US disclosed
US-20070021416-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-01-25 US disclosed
US-20070021476-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides PHARMASCIENCE INC. (CA) 2007-01-25 US disclosed
US-20050069492-A1 Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides PHARMASCIENCE INC. (CA) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021476-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF FYN 2231/4885CA1 748/4885CA2 2366/4885
US-20090042953-A1 IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES PMP22, SMN1; SMN2, BDNF FYN 2703/4885CA1 880/4885CA2 2728/4885
US-20070265319-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF FYN 2231/4885CA1 748/4885CA2 2366/4885
US-20070238766-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF FYN 2231/4885CA1 748/4885CA2 2366/4885
US-20070238768-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF FYN 2231/4885CA1 748/4885CA2 2366/4885
US-20070021416-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF FYN 2231/4885CA1 748/4885CA2 2366/4885
US-20070088059-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF FYN 2231/4885CA1 748/4885CA2 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.